Literature DB >> 7905839

Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment.

J B Wang1, P S Johnson, A M Persico, A L Hawkins, C A Griffin, G R Uhl.   

Abstract

A human mu opiate receptor cDNA has been identified from a cerebral cortical cDNA library using sequences from the rat mu opiate receptor cDNA. The human mu opiate receptor (h mu OR1) shares 95% amino acid identity with the rat sequence. The expressed mu OR1 recognized tested opiate drugs and opioid peptides in a sodium- and GTP-sensitive fashion with affinities virtually identical to those displayed by the rat mu opiate receptor. Effects on cyclic AMP are similar to those noted for the rat mu opiate receptor. An 18 kb genomic clone hybridizing with the h mu OR1 cDNA contains 63 and 489 bp exonic sequences flanked by splice donor/acceptor sequences. Analysis of hybridization to DNA prepared from human rodent hybrid cell lines and chromosomal in situ hybridization studies indicate localization to 6q24-25. An MspI polymorphism, producing a 3.7 kb band, may prove useful in assessing this gene's involvement in neuropsychiatric disorders involving opiatergic systems.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905839     DOI: 10.1016/0014-5793(94)80368-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  54 in total

1.  Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.

Authors:  M Filizola; H O Villar; G H Loew
Journal:  J Comput Aided Mol Des       Date:  2001-04       Impact factor: 3.686

Review 2.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

3.  A new method for evaluating sigma(2) ligand activity in the isolated guinea-pig bladder.

Authors:  Nicola A Colabufo; Francesco Berardi; Marialessandra Contino; Roberto Perrone; Vincenzo Tortorella
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-17       Impact factor: 3.000

4.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 5.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

6.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

Review 7.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway.

Authors:  Cielito C Reyes-Gibby; Xifeng Wu; Margaret Spitz; Razelle Kurzrock; Michael Fisch; Eduardo Bruera; Sanjay Shete
Journal:  Lancet Oncol       Date:  2008-08       Impact factor: 41.316

8.  Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants.

Authors:  Lili Xin; Zaijie Jim Wang
Journal:  AAPS PharmSci       Date:  2002

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Positive transcriptional regulation of the human micro opioid receptor gene by poly(ADP-ribose) polymerase-1 and increase of its DNA binding affinity based on polymorphism of G-172 -> T.

Authors:  Takeshi Ono; Toshio Kaneda; Akihiro Muto; Tadashi Yoshida
Journal:  J Biol Chem       Date:  2009-05-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.